Hansoh’s HS-20197 gains NMPA approval for clinical trials
Hansoh Pharmaceutical says its HS-20197 for injection has received clinical trial approval from China’s NMPA.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.